Robust meta-analytic-predictive priors in clinical trials with historical control information: Robust Meta-Analytic-Predictive Priors. Schmidli, H., Gsteiger, S., Roychoudhury, S., O'Hagan, A., Spiegelhalter, D., & Neuenschwander, B. Biometrics, 70(4):1023–1032, December, 2014. Paper doi abstract bibtex Historical information is always relevant for clinical trial design. Additionally, if incorporated in the analysis of a new trial, historical data allow to reduce the number of subjects. This decreases costs and trial duration, facilitates recruitment, and may be more ethical. Yet, under prior-data conflict, a too optimistic use of historical data may be inappropriate. We address this challenge by deriving a Bayesian meta-analytic-predictive prior from historical data, which is then combined with the new data. This prospective approach is equivalent to a meta-analytic-combined analysis of historical and new data if parameters are exchangeable across trials. The prospective Bayesian version requires a good approximation of the metaanalytic-predictive prior, which is not available analytically. We propose two- or three-component mixtures of standard priors, which allow for good approximations and, for the one-parameter exponential family, straightforward posterior calculations. Moreover, since one of the mixture components is usually vague, mixture priors will often be heavy-tailed and therefore robust. Further robustness and a more rapid reaction to prior-data conflicts can be achieved by adding an extra weakly-informative mixture component. Use of historical prior information is particularly attractive for adaptive trials, as the randomization ratio can then be changed in case of prior-data conflict. Both frequentist operating characteristics and posterior summaries for various data scenarios show that these designs have desirable properties. We illustrate the methodology for a phase II proof-of-concept trial with historical controls from four studies. Robust meta-analytic-predictive priors alleviate prior-data conflicts - they should encourage better and more frequent use of historical data in clinical trials.
@article{schmidli_robust_2014-1,
title = {Robust meta-analytic-predictive priors in clinical trials with historical control information: {Robust} {Meta}-{Analytic}-{Predictive} {Priors}},
volume = {70},
issn = {0006341X},
shorttitle = {Robust meta-analytic-predictive priors in clinical trials with historical control information},
url = {http://doi.wiley.com/10.1111/biom.12242},
doi = {10.1111/biom.12242},
abstract = {Historical information is always relevant for clinical trial design. Additionally, if incorporated in the analysis of a new trial, historical data allow to reduce the number of subjects. This decreases costs and trial duration, facilitates recruitment, and may be more ethical. Yet, under prior-data conflict, a too optimistic use of historical data may be inappropriate. We address this challenge by deriving a Bayesian meta-analytic-predictive prior from historical data, which is then combined with the new data. This prospective approach is equivalent to a meta-analytic-combined analysis of historical and new data if parameters are exchangeable across trials. The prospective Bayesian version requires a good approximation of the metaanalytic-predictive prior, which is not available analytically. We propose two- or three-component mixtures of standard priors, which allow for good approximations and, for the one-parameter exponential family, straightforward posterior calculations. Moreover, since one of the mixture components is usually vague, mixture priors will often be heavy-tailed and therefore robust. Further robustness and a more rapid reaction to prior-data conflicts can be achieved by adding an extra weakly-informative mixture component. Use of historical prior information is particularly attractive for adaptive trials, as the randomization ratio can then be changed in case of prior-data conflict. Both frequentist operating characteristics and posterior summaries for various data scenarios show that these designs have desirable properties. We illustrate the methodology for a phase II proof-of-concept trial with historical controls from four studies. Robust meta-analytic-predictive priors alleviate prior-data conflicts - they should encourage better and more frequent use of historical data in clinical trials.},
language = {en},
number = {4},
urldate = {2019-05-02},
journal = {Biometrics},
author = {Schmidli, Heinz and Gsteiger, Sandro and Roychoudhury, Satrajit and O'Hagan, Anthony and Spiegelhalter, David and Neuenschwander, Beat},
month = dec,
year = {2014},
pages = {1023--1032},
file = {Schmidli et al. - 2014 - Robust meta-analytic-predictive priors in clinical.pdf:/Users/neil.hawkins/Zotero/storage/ZNEBBX9C/Schmidli et al. - 2014 - Robust meta-analytic-predictive priors in clinical.pdf:application/pdf},
}
Downloads: 0
{"_id":"vH44EcBEfx2Y8nom8","bibbaseid":"schmidli-gsteiger-roychoudhury-ohagan-spiegelhalter-neuenschwander-robustmetaanalyticpredictivepriorsinclinicaltrialswithhistoricalcontrolinformationrobustmetaanalyticpredictivepriors-2014","author_short":["Schmidli, H.","Gsteiger, S.","Roychoudhury, S.","O'Hagan, A.","Spiegelhalter, D.","Neuenschwander, B."],"bibdata":{"bibtype":"article","type":"article","title":"Robust meta-analytic-predictive priors in clinical trials with historical control information: Robust Meta-Analytic-Predictive Priors","volume":"70","issn":"0006341X","shorttitle":"Robust meta-analytic-predictive priors in clinical trials with historical control information","url":"http://doi.wiley.com/10.1111/biom.12242","doi":"10.1111/biom.12242","abstract":"Historical information is always relevant for clinical trial design. Additionally, if incorporated in the analysis of a new trial, historical data allow to reduce the number of subjects. This decreases costs and trial duration, facilitates recruitment, and may be more ethical. Yet, under prior-data conflict, a too optimistic use of historical data may be inappropriate. We address this challenge by deriving a Bayesian meta-analytic-predictive prior from historical data, which is then combined with the new data. This prospective approach is equivalent to a meta-analytic-combined analysis of historical and new data if parameters are exchangeable across trials. The prospective Bayesian version requires a good approximation of the metaanalytic-predictive prior, which is not available analytically. We propose two- or three-component mixtures of standard priors, which allow for good approximations and, for the one-parameter exponential family, straightforward posterior calculations. Moreover, since one of the mixture components is usually vague, mixture priors will often be heavy-tailed and therefore robust. Further robustness and a more rapid reaction to prior-data conflicts can be achieved by adding an extra weakly-informative mixture component. Use of historical prior information is particularly attractive for adaptive trials, as the randomization ratio can then be changed in case of prior-data conflict. Both frequentist operating characteristics and posterior summaries for various data scenarios show that these designs have desirable properties. We illustrate the methodology for a phase II proof-of-concept trial with historical controls from four studies. Robust meta-analytic-predictive priors alleviate prior-data conflicts - they should encourage better and more frequent use of historical data in clinical trials.","language":"en","number":"4","urldate":"2019-05-02","journal":"Biometrics","author":[{"propositions":[],"lastnames":["Schmidli"],"firstnames":["Heinz"],"suffixes":[]},{"propositions":[],"lastnames":["Gsteiger"],"firstnames":["Sandro"],"suffixes":[]},{"propositions":[],"lastnames":["Roychoudhury"],"firstnames":["Satrajit"],"suffixes":[]},{"propositions":[],"lastnames":["O'Hagan"],"firstnames":["Anthony"],"suffixes":[]},{"propositions":[],"lastnames":["Spiegelhalter"],"firstnames":["David"],"suffixes":[]},{"propositions":[],"lastnames":["Neuenschwander"],"firstnames":["Beat"],"suffixes":[]}],"month":"December","year":"2014","pages":"1023–1032","file":"Schmidli et al. - 2014 - Robust meta-analytic-predictive priors in clinical.pdf:/Users/neil.hawkins/Zotero/storage/ZNEBBX9C/Schmidli et al. - 2014 - Robust meta-analytic-predictive priors in clinical.pdf:application/pdf","bibtex":"@article{schmidli_robust_2014-1,\n\ttitle = {Robust meta-analytic-predictive priors in clinical trials with historical control information: {Robust} {Meta}-{Analytic}-{Predictive} {Priors}},\n\tvolume = {70},\n\tissn = {0006341X},\n\tshorttitle = {Robust meta-analytic-predictive priors in clinical trials with historical control information},\n\turl = {http://doi.wiley.com/10.1111/biom.12242},\n\tdoi = {10.1111/biom.12242},\n\tabstract = {Historical information is always relevant for clinical trial design. Additionally, if incorporated in the analysis of a new trial, historical data allow to reduce the number of subjects. This decreases costs and trial duration, facilitates recruitment, and may be more ethical. Yet, under prior-data conflict, a too optimistic use of historical data may be inappropriate. We address this challenge by deriving a Bayesian meta-analytic-predictive prior from historical data, which is then combined with the new data. This prospective approach is equivalent to a meta-analytic-combined analysis of historical and new data if parameters are exchangeable across trials. The prospective Bayesian version requires a good approximation of the metaanalytic-predictive prior, which is not available analytically. We propose two- or three-component mixtures of standard priors, which allow for good approximations and, for the one-parameter exponential family, straightforward posterior calculations. Moreover, since one of the mixture components is usually vague, mixture priors will often be heavy-tailed and therefore robust. Further robustness and a more rapid reaction to prior-data conflicts can be achieved by adding an extra weakly-informative mixture component. Use of historical prior information is particularly attractive for adaptive trials, as the randomization ratio can then be changed in case of prior-data conflict. Both frequentist operating characteristics and posterior summaries for various data scenarios show that these designs have desirable properties. We illustrate the methodology for a phase II proof-of-concept trial with historical controls from four studies. Robust meta-analytic-predictive priors alleviate prior-data conflicts - they should encourage better and more frequent use of historical data in clinical trials.},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2019-05-02},\n\tjournal = {Biometrics},\n\tauthor = {Schmidli, Heinz and Gsteiger, Sandro and Roychoudhury, Satrajit and O'Hagan, Anthony and Spiegelhalter, David and Neuenschwander, Beat},\n\tmonth = dec,\n\tyear = {2014},\n\tpages = {1023--1032},\n\tfile = {Schmidli et al. - 2014 - Robust meta-analytic-predictive priors in clinical.pdf:/Users/neil.hawkins/Zotero/storage/ZNEBBX9C/Schmidli et al. - 2014 - Robust meta-analytic-predictive priors in clinical.pdf:application/pdf},\n}\n\n","author_short":["Schmidli, H.","Gsteiger, S.","Roychoudhury, S.","O'Hagan, A.","Spiegelhalter, D.","Neuenschwander, B."],"bibbaseid":"schmidli-gsteiger-roychoudhury-ohagan-spiegelhalter-neuenschwander-robustmetaanalyticpredictivepriorsinclinicaltrialswithhistoricalcontrolinformationrobustmetaanalyticpredictivepriors-2014","role":"author","urls":{"Paper":"http://doi.wiley.com/10.1111/biom.12242"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/f/FfNE7kWA6pCvwcJZF/myPubs.bib","dataSources":["ZaHtWavQhcwZqKLNF","iRRNaRs6FkffgErta","v8uQmZsBpiqycmskv"],"keywords":[],"search_terms":["robust","meta","analytic","predictive","priors","clinical","trials","historical","control","information","robust","meta","analytic","predictive","priors","schmidli","gsteiger","roychoudhury","o'hagan","spiegelhalter","neuenschwander"],"title":"Robust meta-analytic-predictive priors in clinical trials with historical control information: Robust Meta-Analytic-Predictive Priors","year":2014}